Skip to Content

Join the 'Xalkori' group to help and get support from people like you.

Xalkori News

Doctors' Group Offers Ideas for Easing Cancer Costs

Posted 19 Jul 2017 by Drugs.com

WEDNESDAY, July 19, 2017 – New cancer drugs routinely cost $100,000 a year or more, and older cancer drugs are rising in price, too. Now, the American Society of Clinical Oncology (ASCO) has some suggestions for easing patients' money woes. The proposals include allowing Medicare to negotiate drug prices, legalizing the importation of drugs, and adopting bundled, or group, payment programs. In ...

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, ...

Gene-Targeted Drugs Fight Advanced Lung Cancers

Posted 5 Jun 2017 by Drugs.com

MONDAY, June 5, 2017 – Two drugs that target genetic flaws are giving people with specific types of advanced lung cancer a chance to live longer and better, a pair of new clinical trials finds. A newly approved drug called alectinib (Alecensa) works twice as long as the current standard medication in halting cancer growth in patients with ALK-positive non-small cell lung cancer, results from a ...

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less ...

Xalkori Approved For Rare Genetic Form of Lung Cancer

Posted 11 Mar 2016 by Drugs.com

FRIDAY, March 11, 2016 – Xalkori (crizotinib) has been approved by the U.S. Food and Drug Administration to treat advanced non-small cell lung cancer (NSCLC) with tumors that have a rare ROS-1 gene mutation. The drug was approved in 2011 to treat advanced NSCLC that was related to an abnormal ALK gene, the agency said Friday in a news release. Lung cancer is the leading cause of cancer death in ...

FDA Expands Use of Xalkori (crizotinib) to Treat ROS-1 Positive Non-Small Cell Lung Cancer

Posted 11 Mar 2016 by Drugs.com

March 11, 2016 – The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC. Lung cancer is the leading cause of cancer-related deaths in the United States, with an ...

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations ...

Medicines Are Biggest Culprit in Fatal Allergic Reactions: Study

Posted 10 Oct 2014 by Drugs.com

THURSDAY, Oct. 9, 2014 – Although food allergies have garnered a lot of attention lately, a new study reports that medications are actually the biggest cause of sudden deaths related to allergy. Over a little more than a decade, nearly 60 percent of the allergy-related deaths were caused by medications, while less than 7 percent were caused by food allergies, the study found. "Medications can be ...

Experimental Drug Shows Promise for Drug-Resistant Lung Cancer

Posted 26 Mar 2014 by Drugs.com

WEDNESDAY, March 26, 2014 – A new drug may help lung cancer patients when they become resistant to the first-line medication crizotinib, researchers find. Although crizotinib (brand name Xalkori) causes regression of a specific type of lung cancer, patients become resistant to it within about a year. But the new drug, ceritinib, seems effective against this type of lung cancer – called advanced ...

Cancer Chemotherapy Tied to Slight Rise in Risk for Leukemia

Posted 14 Feb 2013 by Drugs.com

THURSDAY, Feb. 14 – Chemotherapy can be a lifesaver for thousands of cancer patients, but a new study suggests that it might slightly raise the odds for a type of leukemia later in life. Over the past 30 years, the risk for acute myeloid leukemia (AML) has increased for patients who underwent chemotherapy for certain forms of cancer, particularly non-Hodgkin lymphoma, the new study found. On the ...

Experimental Drug Helps Fight Some Childhood Cancers, Study Finds

Posted 16 May 2012 by Drugs.com

WEDNESDAY, May 16 – A new targeted drug therapy may help treat certain advanced cancers in children, a new preliminary study indicates. In some cases, the oral medication even made tumors disappear after regular cancer treatments had failed, the researchers reported. "This is an exciting first step, and it looks very promising for kids who have had very few options," said study author Dr. Yael ...

Mixed News on Tough-to-Treat Lung Cancer

Posted 10 Jan 2012 by Drugs.com

TUESDAY, Jan. 10 – Dutch researchers report disappointing results from an early clinical trial of the drug Nexavar (sorafenib) in fighting a tough-to-treat form of lung cancer. But, in better news, an experimental drug known as ganetespib showed promise in laboratory and animal experiments. The results of both studies were to be presented Tuesday at an American Association for Cancer ...

Targeted Drugs, Lung CT Screening Top Cancer Advances in 2011

Posted 6 Dec 2011 by Drugs.com

TUESDAY, Dec. 6 – As the war against cancer continues, a group representing U.S. oncologists has picked its "Top Five" list of advances in cancer care for 2011. Leading the list are approvals for a bevy of new, targeted drugs for tough-to-treat malignancies, plus promising results suggesting CT chest scans may be an early-detection screen for lung cancer. The American Society of Clinical ...

Ask a Question

Further Information

Related Condition Support Groups

Non-Small Cell Lung Cancer

Xalkori Patient Information at Drugs.com